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Abstract
Chronic itch can be caused by dysfunctions of itch-sensing neurons that produce sensory
hallucinations of pruritogenic stimuli. The cellular and molecular mechanisms are still unknown.
All neurological disease categories have been implicated and neurological causes should be
considered for patients with otherwise-unexplained itch. The same neurological illnesses that
cause neuropathic pain can also or instead cause itch. These include shingles (particularly of the
head or neck), small-fiber polyneuropathies, radiculopathies (e.g., notalgia paresthetica and
brachioradial pruritis) and diverse lesions of the trigeminal nerve, root, and central tracts. Central
nervous system lesions affecting sensory pathways, including strokes, multiple sclerosis, and
cavernous hemangiomas can cause central itch. Neuropathic itch is a potent trigger of reflex and
volitional scratching although this provides only fleeting relief. Rare patients whose lesion causes
sensory loss as well as neuropathic itch can scratch deeply enough to cause painless self-injury.
The most common location is on the face (trigeminal trophic syndrome). Treating neuropathic itch
is difficult; antihistamines, corticosteroids, and most pain medications are largely ineffective.
Current treatment recommendations include local or systemic administration of inhibitors of
neuronal excitability (especially local anesthetics) and barriers to reduce scratching.
Many physicians including neurologists are unaware that neurological problems alone can
cause chronic itch. Neuropathic itch and pain are signaling abnormalities – the source of the
problem is not where the symptoms are felt. Like neuropathic pain, neuropathic itch is still
poorly understood despite fundamental advances in understanding the mechanisms of itch in
the normal nervous system.1 Considered physiologically, neuropathic itch is a pathological
form of itch where the stimulus-response curve that governs normal sensation has become
distorted and the itch sensation is out of proportion or even completely independent of any
pruritogenic stimuli. Like an electrical problem in the wiring harness of an automobile, the
actual location and cause of neuropathic itch can be extremely difficult to pin down, but
effective treatment may require anatomical and etiological identification of the neurological
problem and institution of disease-modifying treatment. In some cases, this may be
neurosurgical. Neuropathic itch does not often respond to antihistamines, topical steroids or
other medications effective for conventional itch. Furthermore, like other neurological
symptoms, itch can signal a potentially serious neurological problem that might need
treatment. Most neurology textbooks and training do not discuss the localization and
etiology of errant itch, so not all neurological consultations will be insightful. A
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dermatologist should first examine the patient to exclude conventional causes of itch before
requesting neurological consultation.
What causes neuropathic itch?
The anatomical pathways that mediate normal itch sensation were mentioned previously in
this issue (see “Anatomy and Neurophysiology of Pruritis”, page XXX). Among
somatosensory sensations, itch is the least understood, and the underlying neural circuits are
still in the process of being identified. Virtually nothing is known about the cellular and
molecular bases of itch under pathological circumstances, so this review is based on
fragmentary understanding gleaned from clinical experience and manuscripts largely
restricted to case reports. Findings so far suggest that lesions anywhere in the peripheral
nervous system (PNS) or central nervous system (CNS) that damage itch-transducing,
conducting or processing neurons appear capable of causing neuropathic itch. It is logical to
look for the cause of pruritis in the symptomatic area but the causative lesion may be half a
meter away in a nerve, nerve root, spinal cord or the brain. Like most other neurological
symptoms, what matters is the anatomical location of the lesion, not its etiology.
Neuropathic itch has been associated with most of the major categories of neurological
disease ranging from stroke, tumors and vascular malformations, to demyelinating disease
and radicular compression. This review attempts to summarize the known causes of
neuropathic itch, organized by anatomical location.
Like neuropathic pain, only a fraction of patients with these neurological conditions develop
chronic itch. It appears that neuropathic itch and pain, like many other chronic conditions,
are likely complex conditions in which a specific trigger, neuronal damage, increases risk
for symptoms in individuals with underlying susceptibility. There are no data about what the
environmental and genetic risk factors for neuropathic itch might be. In the pain field, a
fruitful approach has been to screen electronic records for premorbid conditions present
prior to the onset of the symptoms.2 Also unexplained is why a particular illness, zoster for
instance, leaves some patients with neuropathic pain, some with neuropathic itch, most with
neither, and some with both. At least in some cases, neuropathic pruritis can persist. There
are several reports of patients with new self-induced injury decades after strokes or
trigeminal surgery when dementia caused their scratching to become uncontrolled.3,4 In
addition to sensing pain and itch, the small-diameter unmyelinated and thinly myelinated
axons that carry itch and pain sensation (“small-fibers”) have diverse efferent and trophic
actions that are usually related to response to injury. These include microvascular and
immune changes (neurogenic inflammation) that may also contribute to itch (e.g., via
recruitment of mast cells). These can provide objective evidence that helps identify when
itch is neuropathic.5
Painless self-injury from neuropathic itch
The worst complication is self-injury from scratching. Itch patients often develop skin
changes from prolonged scratching (e.g. lichenification), but scratching into deeper tissues is
virtually pathognomonic for neuropathic itch. For this to develop requires not only
intractable itch, but also co-localizing severe sensory loss that renders scratching painless
and permits it to continue to the point of self injury. Impaired self-control undoubtedly
contributes, although most patients with this are psychiatrically normal. It is nearly
impossible to continually resist the urge to scratch a severe chronic itch, and scratching can
occur during sleep or at times of inattention. Interestingly, patients and even their physicians
may not always understand that their lesions are self-generated.
Painless self-injury from neuropathic itch is far more common on the face than anywhere
else on the body. The reasons are unknown, but studying shingles patients showed that
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postherpetic itch is far more common after zoster affecting the face than the torso,
preliminary evidence of regional variability in susceptibility to neuropathic itch.6 The face is
also unclothed and readily accessible to the fingers; indeed many people engage in absent-
minded stereotyped digital facial stimulation (e.g., nose picking, hair twirling), just not to
the point of self injury. See the section on facial itch later in this paper for more on
trigeminal trophic syndrome (TTS).
Major neuropathic itch syndromes and how to diagnose them
Small-fiber polyneuropathy (axonopathy)
It seems appropriate to begin at the skin and proceed proximally. The skin is richly
innervated with the small unmyelinated (C-fiber) and thinly myelinated axons (A-delta
fibers) that transmit itch and pain sensations (nociception).7 The term small-fiber
polyneuropathy (SFPN) is used for conditions associated with widespread damage or
dysfunction of these axons, usually due to systemic or general causes. Some
polyneuropathies are highly specific for one particular kind of axon, and itch is specifically
associated with neuropathy of the small-diameter axons that transduce and transmit pain and
itch. In contrast, sensory neuropathies that predominantly affect the large sensory fibers
cause poor balance and loss of touch and joint position sense, and motor axonopathies
produce weakness and muscle atrophy. Since itch-fibers are unmyelinated or thinly
myelinated, polyneuropathies that damage myelin are unlikely to produce itch as a major
symptom. In practice, inflammation and degeneration of a particular axonal subtype often
causes varying amounts of “bystander” damage to adjacent axons even if they are not
directly targeted. The most common cause of small-fiber polyneuropathy in developed
countries is diabetes mellitus, and even pre-diabetes and impaired glucose tolerance.8 Other
important causes include vitamin deficiencies, exposure to toxins including cancer
chemotherapy and other medications, and plasma-cell dyscrasias.9 Identifying and treating
these underlying causes is the best way to ameliorate accompanying pruritis.
SFPN usually begins in both feet, innervated by the longest axons, and then the hands
typically become involved as symptoms ascend past the knees (Figure 1). Occasional
patients present with proximal or diffuse symptoms due to autoimmune attack or other cause
of degeneration centered in the sensory ganglia (see below).10 Diagnosis of SFPN can be
difficult because motor signs are absent and standard electrodiagnostic testing
(electromyography/nerve conduction study) is insensitive. Normal nerve conduction study
results do not preclude a diagnosis of small-fiber neuropathy. The American Academy of
Neurology endorses two objective tests for diagnosing SFPN;11 distal-leg skin biopsies
immunolabeled to show the density and morphology of epidermal nerve-fibers (ENF),12 and
autonomic-function testing (AFT), which quantitates cardiovascular responses and
sweating.13 Both tests are available at select academic centers.
Dermatologists are well-qualified to perform skin biopsy for diagnosis of SFPN, but need to
know that biopsies need to be taken from a standard site, 10 cm proximal to the lateral
malleolus in an area with healthy skin, and they need to be immediately fixed in special
fixatives (PLP or Zamboni’s) and sent to an academic or commercial laboratory that
analyzes such biopsies (these include Johns Hopkins and the Massachusetts General
Hospital). Because the punch diameter (usually 3 mm) will figure into calculations of ENF
density, punches need to be removed without significantly indenting (stretching) the skin
and anesthesia needs to be injected subcutaneously rather than intradermally. The biopsy site
should not be sutured and should be covered for 7–10 days. Unlike sural nerve biopsies, skin
biopsies can be repeated to monitor disease progression or response to therapy. Biopsies are
usually immunolabeled with an antibody against PGP9.5, a pan-axonal marker. This enables
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the small sensory nerve endings in the epidermis to be counted with light microscopy.
Normative data provide reference ranges.14
Shingles and other lesions of the neurosensory ganglia
The spine and skull protect the ganglia from trauma but often cause radicular compression
(pinched nerve) when distorted by osteoarthritis. Paraneoplastic syndromes and other
autoimmunity (e.g., Sjögren’s syndrome) are rare causes of ganglionopathy as well as
brachial and lumbosacral plexopathies.15 By far the most common sensory ganglionitis that
causes neuropathic itch is shingles (herpes zoster). The cause is reactivation of endogenous
dormant varicella zoster virus and this kills a proportion of sensory neurons.16 The most
common sequel is post-herpetic neuralgia (PHN), which occurs in some 10–15 of cases in
unvaccinated patients.16 PHN is chronic neuropathic pain persisting more than 3 months
after the shingles rash resolves; the risk is age-proportional and reduced by vaccination.17
There is growing awareness among physicians that chronic post-herpetic itch (PHI) is
another potentially disabling consequence of zoster, although many patients have personal
awareness of this. PHI and PHN can ensue independently or together after shingles, and
with varying relative severities. The most likely assumption (as yet unproven) is that,
analogous to PHN, PHI is a system disorder caused by lasting injury to neurons that mediate
normal itch sensations. Epidemiological study revealed PHI to be reported by one-third to
one-half of shingles patients, and prevalence is greater after shingles on the face or neck
than on the torso.6 It is usually mild or moderate in intensity, but occasional cases with self-
injury have been reported in association with severe enough small-fiber loss to render the
continued scratching painless.18 Medications shown effective for PHN may not help PHI,
which seems overall more difficult to treat. Opioids are documented effective for PHN, but
they often precipitate or worsen itch.19 PHN is often studied in large clinical trials of new
treatments for neuropathic pain designed to meet requirements of the Food and drug
Administration. We could learn much about effective therapies by including PHI as an
additional outcome.
Radicular itch and spinal nerve-root compression (brachioradial pruritis and nostalgia
paresthetica)
Nerve roots are vulnerable to compression and many radiculopathies are traumatic in origin.
The hallmark of a radiculopathy is localization of symptoms largely to the body areas
innervated by one or more of the nerve roots as they exit the brain and spinal cord; almost
always, radiculopathies are unilateral. Neurologists and neurosurgeons have long known
about these syndromes and know that patients presenting with radicular patterns of sensory
or motor complaints may need spinal imaging and evaluation for decompressive
neurosurgery. Other less-common causes of radiculopathy include neoplastic and
granulomatous infiltrations, and intrinsic neuropathies that have a predilection for this
location, including diabetic truncal radiculopathy (a vasculitis). Self-mutilation of the hand
or arm in young children with brachial-plexus injuries sustained at childbirth may be another
form of neuropathic radicular itch.20 Notalgia paresthetica and brachioradial pruritis are
dermatological terms that describe one or more focal itchy patches of unknown etiology
located on the torso or upper arms respectively. Nerve-root compression from degenerative
spine is their most common cause,21 and it is likely that the other radiculopathies mentioned
above cause some of the non-compressive cases.22
Cranial nerve and root lesions that can cause itch of the throat, jaw, and ear
Damage to the cranial nerves that contain somatosensory fibers can cause pruritis. Like
spinal nerves and roots, cranial nerves can be acutely compressed if they swell (e.g. from
viral infection) and chronically compressed by narrowing of the bony foramina from
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osteoarthritis and other causes. The trigeminal nerve (V) that innervates most of the face is
discussed below, but damage to peripheral or central somatosensory axons of VII, IX, and X
can also cause neuropathic itch and pain. Viruses or rare structural lesions can damage
peripheral axons, and stroke, multiple sclerosis, and neoplastic, infectious or degenerative
diseases cause most central lesions. Radiographic imaging is indicated for new syndromes to
identify potential structural causes and lumbar puncture can help identify infectious or
autoimmune causes. When neurologists fail to find a lesion, a previous viral infection is
often presumed.
The facial nerve (VII) is mostly motor, but it also provides somatosensory innervations to
the external surface of the tympanic membrane, the outer ear canal, a piece of skin behind
the ear, and part of the cheek anterior to the ear including the tragus via the nervus
intermedius. This area is variably sized, in some patients including half of the cheek. The
glossopharyngeal nerve (IX) carries pain, temperature, and probably also touch from the
posterior third of the tongue, the internal surface of the tympanic membrane, and the pinna
(external ear). Lesions including zoster can leave chronic pain (glossopharyngeal neuralgia)
and or itch (glossopharyngeal pruritis) in the throat or behind the angle of the jaw. The
vagus (X) is a primarily motor, parasympathetic and visceral sensory nerve that also
transmits pain, touch, and temperature from the larynx, pharynx, part of the pinna, external
tympanic membrane, and ear canal, and the meninges of the posterior fossa. Itch sensation is
restricted to the mucosa and skin, and is not thought to be present within the body. Some
patients with itch from IX or X lesions report a “tickle” in their throat that causes chronic
cough, a significant disability.
Trigeminal nerve and root lesions that cause facial itch, including trigeminal trophic
syndrome
The only cranial nerve clearly linked to a specific itch syndrome is the trigeminal (V), which
innervates most of the face, sinuses, and cranial cavity. Although trigeminal nerve lesions
are best known for causing neuropathic pain (trigeminal neuralgia and neuropathy), they
also cause chronic itch syndromes. Shingles is a well-known cause, it more often affects the
ophthalmic (V1) than the maxillary (V2) or mandibular (V3) divisions. Compression of the
intracranial portion of V by an errant blood vessel is increasingly recognized as the most
common cause of trigeminal neuralgia. A similar etiology should be considered, particularly
in patients with onset at middle age or older. In contrast, onset in patients under 30 years
should prompt consideration of multiple sclerosis, particularly in women or when ilateral.
Peripheral lesions that can cause central neuropathic itch and trigeminal trophic
syndrome (TTS)
Although most physicians know about trigeminal neuralgia, far fewer know about the
corresponding neuropathic itch syndrome, or its major complication, TTS. Throughout the
20th century, the major cause of trigeminal itch manifesting as TTS was surgical destruction
of the ipsilateral trigeminal (Gasserian) ganglion or its peripheral root to treat trigeminal
neuralgia.23,24 One series reported 18% prevalence of TTS after trigeminal ablation.25
Before the invention of the first effective medications for neuralgia, carbamazepine and
phenytoin, severe trigeminal neuralgia was treated surgically.26 The combination of dense
sensory loss and chronic itch produced a surge in TTS cases. Some patients also had
deafferentation pain (anesthesia dolorosa). The lesions were first attributed to impaired
vitality of deafferented skin from loss of neuronal trophic factors, hence the name. It was
only gradually recognized that TTS lesions are self inflicted by scratching, desensate itchy
denervated skin. Rare peripheral causes of TTS include compressive skull-base tumors such
as meningiomas and acoustic neuromas.27,28 Neurological evaluation is indicated for all
unexplained cases. Rare infectious causes include Herpes simplex and leprosy.29,30
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TTS can appear anywhere in the trigeminal innervation territory,18 but is most characteristic
at the ipsilateral nasal ala and adjacent cheek and upper lip, in V2 or V3 territory (Figure 2).
The usual sparing of the tip of the nose is attributed to its innervation by the external nasal
branch of the anterior ethmoidal nerve, a branch of V1. Most attempts to destroy the
trigeminal ganglion or root try to spare V1, to prevent blindness from inadvertent trauma to a
desensate cornea no longer protected by the blink reflex (neuropathic keratitis).23
Alternately, the tip of the nose might retain innervation from the intact contralateral nerve.
Brain lesions that can cause central neuropathic itch and trigeminal trophic syndrome
Central causes of neuropathic pain are not as common as peripheral causes. There is no one
particular disease that causes central neuropathic itch; it can occur with any disease that
affects the ascending pain pathways.31 Brain lesions reportedly cause 21% of TTS, most
often from strokes.32,33 Less common causes include multiple sclerosis,34 brain tumors,35
abscesses,36 and Sjögren’s syndrome.32 Rare cases have also been attributed to anterior
circulation stroke, particularly those that affect the thalamus.33 Exceptionally rare cases
involve syrinxes or tumors of the medulla or pons.37 Radiographic imaging of such patients
can help identify the central itch pathways.
The Wallenberg or lateral medullary syndrome, which can also cause neuropathic facial
pain, is the best-known cause.38,39 The complete syndrome is caused by infarction of a
wedge of lateral medulla, in most cases from vertebral-artery blockage. Occasional cases are
attributed to smaller strokes in this same territory, for instance involving the posterior
inferior cerebellar artery (PICA),40,41 or thalamus. 33 The full picture includes signs of
abnormality of the vestibular system (vertigo, nystagmus, oscillopsia, vomiting),
spinothalamic tract (ipsilateral loss of body pain and temperature), descending sympathetic
tract (ipsilateral Horner syndrome) and cranial nerves IX and X (hoarseness and choking),
otolithic nucleus (double vision), cerebellar connections (ipsilateral ataxia), as well as the
descending tract and nucleus of the trigeminal (V) nerve causing loss of pain and
temperature on the ipsilateral face. Because the medial sensory pathways are supplied by a
different artery, nociceptive sensations (pain and temperature) are damaged but the non-
nociceptive sensations (e.g., touch, vibration, proprioception) that ascend in the medial
lemniscus and the pyramidal tract carrying motor function are spared. The two sensory
pathways converge in the upper brainstem, so more rostral lesions damage all sensory
modalities and do not seem likely to cause this syndrome.
Spinal-cord lesions
Spinal-cord injury can combine injuries to both the central axons of peripheral neurons and
secondary and tertiary neurons entirely within the CNS. There are only about a dozen
reports of intramedullary pruritis, although doubtless many cases go unrecognized. Again,
various causative lesions have been described, including trauma causing hemi-body itch as
part of the Bown-Séquard syndrome,42 syringomyelia,43 and multiple sclerosis.34 The best
documented is intramedullary cavernous hemangioma (cavernoma). These rare congenital
malformations comprise less than 5% of all intramedullary lesions. So when we described
the third case of neuropathic itch associated with intramedullary cavernoma, we posited a
specific association based on their relatively rostro-dorsal location and microscopic
pathology.44 Data from patients with shingles, notalgia, and brachioradial pruritis suggests a
rostro-caudal gradient of susceptibility to neuropathic itch.6 We also suggested that the
hemosiderin-laden phagocytes in their rim might be fostering ectopic firing of nearby
neurons to makes cavernomas highly pruritogenic as well as epileptogenic (when
intracranial).44
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We studied a rat model of spinal-cord injury to further investigate these hypotheses.
Microinjecting excitotoxic quisqualate into the dorsal spinal cord of rats produces gliotic
cavities like those caused by cavernomas. Some such injected rats begin to scratch and bite
at the dermatome on their flank innervated by the damaged spinal-cord segment.45 Such
autotomy develops only in rats whose injection destroys the deep dorsal horn, suggesting
such damage may be requisite for developing central spinal itch.46 The cell bodies of
second-order, histamine-triggered itch neurons are in lamina I of the dorsal horn, from there
ascending via the contralateral lateral spinothalamic tract to the thalamus.47 We
hypothesized that central itch ensued when these lamina I neurons were preserved but near
the lesion and firing excessively due to hemosiderin and gliosis.46 In these rats, even though
the spinal cord was injected, skin biopsies showed profound loss of small-fibers in the skin,
so peripheral deafferentation may also contribute.46
Treatment of neuropathic itch
Behavioral treatments are foremost. Surprisingly, patients often do not understand that their
scratching is the cause of their skin lesions, and may attribute the itch to the lesions rather
than the converse. Explaining the cause of the patients’ itch and its potential for self-injury
will in many cases be enough to break habitual scratching. However, considerable
scratching occurs when patients are asleep or inattentive, so patients with impending or
actual ulcers may need to use protective garments to shield their lesions from involuntary
scratching. In one patient who scratched through her skull, locking the helmet that she wore
to protect her skull defect was the most effective treatment.18
Among medications, local anesthetics – whether administered topically, by local injection,
or systemically – have proven paramount. These inhibit neuronal firing and affect small-
fiber firing at lower doses than required to block motor conduction. High thoracic epidural
infusion of bupivicaine and clonidine reportedly helped one patient with V1 PHN and PHI.48
There is also limited evidence of efficacy for other inhibitors of action potentials including
carbamazepine.34 Mexiletine, an oral analogue of lidocaine is also reasonable to consider.49
There are isolated case reports of efficacy of pregabalin,43
Some patients with disfiguring facial ulcers and exposed bone require surgical repair,50 but
these will not succeed unless scratching is controlled. Surgical flaps should be well-
innervated as well as vascularized. This may require rotation from outside of the affected
dermatome, and perhaps from the other side of the face.51
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Figure 1. A patient with chronic itch and scratching-induced lesions on her distal legs
negligible sweat production from the forearm, proximal leg, distal leg and foot sites after
iontophoresis of acetylcholine, reflecting dysfunction of her cholinergic sudomotor sweat
fibers, consistent with small-fiber polyneuropathy.
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Figure 2. A man with trigeminal trophic syndrome
This 63-year-old developed left trigeminal itch and pain after left Wallenberg’s syndrome
(dorsolateral medullary infarction). His trigeminal trophic syndrome (TTS) was maintained
by his scratching. Reproduced with permission from Elsevier.39
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